NEJM :戒酒有助于降低房颤复发风险

2020-01-02 MedSci MedSci原创

研究认为,戒酒可减少常饮酒者房颤复发风险

过量饮酒可导致房颤和心房重塑,然而戒酒对房颤的二级预防效果尚不清楚。

近日,研究人员在澳大利亚的六家医院进行了一项多中心、前瞻性、开放性、随机、对照试验。每周饮用10单位或以上标准酒精饮品(约12克纯酒精为1单位标准饮品),并在基线时窦性心律出现阵发性或持续性心房颤动的成年人参与研究,随机接受戒酒或不干预。研究包含两个主要终点,其一为6个月期间无房颤复发,其二为总房颤负担。

140名患者参与研究,其中85%为男性,平均年龄62岁,70人接受戒酒,70人不干预。戒酒组患者每周饮酒量从16.8单位减少到2.1单位,减少87.5%,而对照组患者每周饮酒量从16.4单位减少到13.2单位,减少19.5%。在2周的消隐期后,戒断组70例中有37例(53%)再次出现房颤,对照组70例中有51例(73%)复发。戒断组,复发前的无房颤时间比对照组长(危险比为0.55)。随访6个月以上,戒断组房颤负担明显低于对照组(房颤发作的中位时间百分比,0.5% vs.1.2%)。

研究认为,戒酒可减少常饮酒者房颤复发风险。

原始出处:

Aleksandr Voskoboinik et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med, January 2, 2020.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905544, encodeId=64c219055446a, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Oct 11 11:50:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377749, encodeId=76523e77490a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Jan 03 23:17:13 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031209, encodeId=0392103120919, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jan 02 22:50:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035077, encodeId=aaab10350e780, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jan 02 22:50:00 CST 2020, time=2020-01-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905544, encodeId=64c219055446a, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Oct 11 11:50:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377749, encodeId=76523e77490a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Jan 03 23:17:13 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031209, encodeId=0392103120919, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jan 02 22:50:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035077, encodeId=aaab10350e780, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jan 02 22:50:00 CST 2020, time=2020-01-02, status=1, ipAttribution=)]
    2020-01-03 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1905544, encodeId=64c219055446a, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Oct 11 11:50:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377749, encodeId=76523e77490a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Jan 03 23:17:13 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031209, encodeId=0392103120919, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jan 02 22:50:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035077, encodeId=aaab10350e780, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jan 02 22:50:00 CST 2020, time=2020-01-02, status=1, ipAttribution=)]
    2020-01-02 心介

    房颤,临床上碰到很多哦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1905544, encodeId=64c219055446a, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Sun Oct 11 11:50:00 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=377749, encodeId=76523e77490a, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Jan 03 23:17:13 CST 2020, time=2020-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1031209, encodeId=0392103120919, content=房颤,临床上碰到很多哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=心介, createdTime=Thu Jan 02 22:50:00 CST 2020, time=2020-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035077, encodeId=aaab10350e780, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jan 02 22:50:00 CST 2020, time=2020-01-02, status=1, ipAttribution=)]
    2020-01-02 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Diabetes Obes Metab:2型糖尿病增加了房颤患者心衰和死亡的长期风险

由此可见,伴有房颤的T2DM患者新发/复发性HF事件、心血管疾病和全因死亡率的风险增加,特别是在接受胰岛素治疗的情况下。新发HF的主要表型为HFpEF。T2DM导致HFpEF和HFmrEF/HFrEF的风险更高。

Circulation:房颤患者服用NSAIDs和抗凝药对出血风险和心血管预后的影响

服用非甾体抗炎药(NSAIDs)与口服抗凝剂与出血风险增加有关。本研究对服用NSAIDs和阿哌沙班或华法林的房颤患者的出血风险和主要心血管预后进行评估。ARISTOTLE试验(阿哌沙班用于降低房颤患者的卒中和其他血栓栓塞事件,19201位受试者)对比阿哌沙班和华法林用于房颤患者的卒中风险增加情况。排除重度肝肾疾病的患者,共17423位被纳入分析。根据NSAIDs使用情况分层(一直使用、中间使用、一

Hypertension:血压变异性与房颤发病率

由此可见,该研究的结果表明,较高的血压变异性与适度增加的房颤风险有关。

Stroke:利伐沙班和华法林治疗的房颤患者卒中和死亡的风险

由此可见,初步诊断为房颤后,利伐沙班和华法林治疗的患者卒中风险显著降低,尤其是严重卒中和卒中后全因死亡率。这项观察性研究的结果可能有助于为非瓣膜性房颤患者卒中预防选择合适的抗凝药物。

Circulation:急性冠脉综合征合并房颤患者的更佳抗凝方案!

抗血栓治疗方案的安全性和有效性可能在采用不同治疗方式(经药物治疗、经皮冠状动脉介入治疗[PCI]和选择性PCI)的有房颤表现的ACS患者之间存在差异。研究人员采用2x2的方案设计,对比阿哌沙班和维生素K拮抗剂、阿司匹林和安慰剂用于ACS、进行PCI或采用P2Y12抑制剂治疗的有房颤表现的患者的疗效和安全性。共招募了4614位患者,其中1097位(23.9%)采用药物治疗,1714位(37.3%)采

抗凝可防房颤患者痴呆发生

很多都发现房颤会增加痴呆风险,比如兰州大学第二医院学者研究就,高达40%的房颤患者存在血管性痴呆。不过抗凝治疗到底是能预防痴呆还是因可能增加脑微出血风险而增加痴呆?阿司匹林管用吗?